PharmaTelevision - Bristol-Myers Squibb’s New Direction

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Bristol-Myers Squibb’s New Direction

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

Bristol-Myers Squibb is a company that has undergone distinct changes in the last few years. Timothy Herpin explains the thoughts behind their new, broader strategy and their aims to re-invent themselves as a biopharma company becoming more innovative and less integrated. Part of their aim is to source more partners and, since the failed acquisition attempt of ImClone, the company is cash-rich and actively looking to expand its portfolio.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Next Generation Biopharma strategy and the strategic transactions group.

Fintan Walton:

Hello and welcome to Pharmaventures business review here in Melbourne Australia. On this show I have Tim Herpin who is a director in the Strategic transaction group at Bristol-Myers Squibb. Welcome to show.

Timothy Herpin :

Thank you.

Fintan Walton:

Tim , Bristol-Myers Squibb is a company that has undergone a lot of changes in the last few years and in particular it's the development of the strategic transactions group which you are a member of and that fits within this broader strategy that Bristol-Myers Squibbhas taken and could you describe that particular strategy, where the strategic transaction group fits in that within that strategy?

Timothy Herpin :

So with the arrival of our new CEO James M.Cornelius a couple of years ago BMS , embarked into a new strategy that aims to bring together the best of biotech and best of pharma into what we call the next generation bio pharma strategy and what it means for us is really moving forward as a company we want to try to focus on unmet medical need and be more innovative as a company. We also want to be less integrated so we want to rely more on partnerships to actually do our business.

Fintan Walton:

So this is a big change I mean both people when they look at Bristol-Myers Squibb look at it as a large US corporation and it's to have an aspiration to become a biotech company?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Timothy Herpin

Director, Strategic Transaction Group

Timothy Herpin is currently Director, Strategic Transaction Group at Bristol-Myers Squibb. In this role, he identifies and evaluates licensing opportunities in the areas of Cardiovascular and Metabolic Diseases. He also manages preclinical alliances. Prior to this position, Tim worked as a medicinal chemist at Bristol-Myers Squibb, Aventis and Pharmacopeia. Tim is a graduate of Ecole Polytechnique in France, holds a Ph.D. in organic chemistry from the University of London and an MBA in Finance from NYU Stern.

Bristol-Myers Squibb

Bristol-Myers Squibb , colloquially referred to as BMS , is a global biopharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY and Squibb Corporation . The company's primary R&D sites are located in Lawrenceville, New Jersey and Wallingford, Connecticut, with other sites around the US, in Ireland and in other countries worldwide. Their R&D strategy is to pursue significant areas of unmet medical need by leveraging their legacy in discovering and developing high-potency small molecules as well as their growing experience and expertise in highly targeted biologics. The Strategic Transactions Group, headed up by Jeremy Levin, supports R&D in identifying, reviewing, and developing collaborative agreements with organizations.